Julia Beck
Overview
Explore the profile of Julia Beck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Gladbach Y, Sklarz L, Roolf C, Beck J, Schutz E, Fuellen G, et al.
Genes (Basel)
. 2022 Jul;
13(7).
PMID: 35886023
Little is known about optimally applying chemotherapeutic agents in a specific temporal sequence to rapidly reduce the tumor load and to improve therapeutic efficacy. The clinical optimization of drug efficacy...
22.
Baumann A, Beck J, Kirchner T, Hartleben B, Schutz E, Oellerich M, et al.
Liver Transpl
. 2022 Apr;
28(12):1911-1919.
PMID: 35429207
Personalized immunosuppression (IS) promises to improve the balance of necessary control of alloreactivity and dose-dependent adverse effects of long-term IS such as kidney insufficiency, infections, and malignancies. The majority of...
23.
Schrezenmeier E, Rincon-Arevalo H, Jens A, Stefanski A, Hammett C, Osmanodja B, et al.
JCI Insight
. 2022 Mar;
7(9).
PMID: 35349490
Transplant recipients exhibit an impaired protective immunity after SARS-CoV-2 vaccination, potentially caused by mycophenolate (MPA) immunosuppression. Recent data from patients with autoimmune disorders suggest that temporary MPA hold might greatly...
24.
Packeiser E, Taher L, Kong W, Ernst M, Beck J, Hewicker-Trautwein M, et al.
Cancer Cell Int
. 2022 Feb;
22(1):54.
PMID: 35109825
Background: Canine prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) are typically characterized by metastasis and chemoresistance. Cell lines are important model systems for developing new therapeutic strategies. However, as...
25.
Braicu E, du Bois A, Sehouli J, Beck J, Prader S, Kulbe H, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008332
Background: Chromosomal instability, a hallmark of cancer, results in changes in the copy number state. These deviant copy number states can be detected in the cell-free DNA (cfDNA) and provide...
26.
Kong W, Sender S, Taher L, Villa-Perez S, Ma Y, Sekora A, et al.
Int J Mol Sci
. 2021 Dec;
22(23).
PMID: 34884478
Bruton's tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K) in the B-cell receptor (BCR) signaling pathway are considered potential therapeutic targets for the treatment of B-cell lymphomas, among which, diffuse large...
27.
Thiemeyer H, Taher L, Schille J, Packeiser E, Harder L, Hewicker-Trautwein M, et al.
Int J Mol Sci
. 2021 Nov;
22(21).
PMID: 34768937
Prostate cancer (PCa) in dogs is a highly malignant disease akin to its human counterpart. In contrast to the situation in humans, multi-gene approaches facilitating risk stratification of canine PCa...
28.
Osmanodja B, Akifova A, Budde K, Choi M, Oellerich M, Schutz E, et al.
Transplant Direct
. 2021 Oct;
7(11):e778.
PMID: 34712778
Background: Donor-derived cell-free DNA (dd-cfDNA) is increasingly recognized as a valuable biomarker for acute transplant injury, with possible indications in the detection of cellular or humoral rejection and the guidance...
29.
Oellerich M, Sherwood K, Keown P, Schutz E, Beck J, Stegbauer J, et al.
Nat Rev Nephrol
. 2021 May;
17(9):591-603.
PMID: 34031575
In kidney transplantation, the use of minimally invasive damage biomarkers that are more sensitive and specific than plasma creatinine will be crucial to enable early, actionable detection or exclusion of...
30.
Knuttgen F, Beck J, Dittrich M, Oellerich M, Zittermann A, Schulz U, et al.
Transplantation
. 2021 Mar;
106(3):615-622.
PMID: 33653997
Background: Circulating graft-derived cell-free DNA (dd-cfDNA) is a new marker of cardiac allograft damage that is used for noninvasive rejection diagnostics. We performed dd-cfDNA (%) in heart transplant recipients during...